“Outside the Box” Drug Combinations for Multidrug-Resistant Acinetobacter baumannii

Ceftazidime/avibactam, meropenem, and ampicillin/sulbactam combined with cefiderocol were effective in a mouse model of cefiderocol-resistant A. baumannii.

Establishing effective combination regimens for carbapenem-resistant Acinetobacter baumannii (CRAB) therapy has been hampered by heterogeneity of patients. Moreover, despite reliable activity in vitro of the newly developed antibiotic cefiderocol against CRAB, some questions remain about its clinical use due to higher all-cause mortality compared with best available therapy (NEJM JW Infect Dis May 2022 and Antimicrob Agents Chemother 2022 Mar 21; [e-pub]). Now, Gill et al. evaluated cefiderocol alone or in combination with ampicillin/sulbactam (AS), meropenem (M), or ceftazidime/avibactam (CZA) in a neutropenic mouse thigh infection model. The A. baumannii strains tested included 3 cefiderocol-high-end-susceptible isolates (MIC 2 mg/L) and …

Reviewing Author

George Sakoulas, MD

Disclosures

Consultant/Advisory BoardParatek Pharmaceuticals; Nestle Corp.; AbbVie; Shionogi

Speaker’s BureauAllergan/AbbVie; Paratek Pharmaceuticals; Nestle Corp.

RoyaltiesUpToDate

Editorial BoardsAntimicrobial Agents and Chemotherapy; Open Forum Infectious Diseases

George Sakoulas, MD

Disclosures

Consultant/Advisory BoardParatek Pharmaceuticals; Nestle Corp.; AbbVie; Shionogi

Speaker’s BureauAllergan/AbbVie; Paratek Pharmaceuticals; Nestle Corp.

RoyaltiesUpToDate

Editorial BoardsAntimicrobial Agents and Chemotherapy; Open Forum Infectious Diseases

“Outside the Box” Drug Combinations for Multidrug-Resistant Acinetobacter baumannii

Topics

Reviewing Author